Aims and scope

Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports.

Although the primary focus is Alzheimer's dementia, the scope encompasses translational research into other neurodegenerative diseases.

Featured research article: Mild versus moderate stages of Alzheimer's disease in routine clinical practice of ChEI therapy

In this study, Carina Wattmo and colleagues aim to describe and compare various aspects of disease progression in patients with mild versus moderate AD in routine clinical practice of cholinesterase inhibitor (ChEI) therapy using a 3-year, prospective, observational, multicentre study. The study highlights the clinical importance of instrumental ADL evaluations in patients at a mild stage of AD, and the importance of optimizing the ChEI dose even for individuals with moderate AD.

Carina Wattmo, Lennart Minthon and Åsa K. Wallin
Alzheimer's Research & Therapy 2016 8:7

Featured review: Lung disease as a determinant of cognitive decline and dementia

This review, from Dodd, summarises the evidence of an association between cognition, impaired lung function and obstructive lung disease. It goes on to examine the contribution of neuro-imaging to our understanding of the underlying pathophysiology. While the mechanisms of brain pathology and cognitive impairment are likely to be complex and multi-factorial, there is evidence to suggest a key role for occult cerebrovascular damage independent of traditional vascular risk factors, including smoking.

Alzheimer's Research & Therapy 2015 7:32

Editors-in-Chief

Alzheimer's Research & Therapy is edited by Philip Scheltens and Todd Golde. Find the full Editorial Board here.

Articles

Recent articles

View all articles

Most accessed articles

Most Accessed Articles: Alzheimer's Research & Therapyhttp://alzres.biomedcentral.comMost Accessed Articles: Alzheimer's Research & TherapyStem cell factor and granulocyte colony-stimulating factor reduce β-amyloid deposits in the brains of APP/PS1 transgenic micehttp://alzres.biomedcentral.com/articles/10.1186/alzrt67Alzheimer's disease (AD) is widely recognized as a serious public health problem and heavy financial burden. Currently, there is no treatment that can delay or stop the progressive brain damage in AD. Recently...Tue, 15 Mar 2011 00:00:00 GMThttp://alzres.biomedcentral.com/articles/10.1186/alzrt67Bin Li, Maria E Gonzalez-Toledo, Chun-Shu Piao, Allen Gu, Roger E Kelley and Li-Ru Zhao2011-03-15T00:00:00ZBACE1 inhibitor drugs in clinical trials for Alzheimer’s diseasehttp://alzres.biomedcentral.com/articles/10.1186/s13195-014-0089-7β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is the β-secretase enzyme required for the production of the neurotoxic β-amyloid (Aβ) peptide that is widely considered to have a crucial early role ...Wed, 24 Dec 2014 00:00:00 GMThttp://alzres.biomedcentral.com/articles/10.1186/s13195-014-0089-7Robert Vassar2014-12-24T00:00:00ZFirst-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease modelhttp://alzres.biomedcentral.com/articles/10.1186/alzrt278We have identified structural determinants on tau protein that are essential for pathological tau–tau interaction in Alzheimer’s disease (AD). These regulatory domains, revealed by monoclonal antibody DC8E8, r...Fri, 01 Aug 2014 00:00:00 GMThttp://alzres.biomedcentral.com/articles/10.1186/alzrt278Eva Kontsekova, Norbert Zilka, Branislav Kovacech, Petr Novak and Michal Novak2014-08-01T00:00:00ZAlzheimer’s disease drug-development pipeline: few candidates, frequent failureshttp://alzres.biomedcentral.com/articles/10.1186/alzrt269Alzheimer’s disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N-methyl-D-aspartate (NMDA)-receptor...Thu, 03 Jul 2014 00:00:00 GMThttp://alzres.biomedcentral.com/articles/10.1186/alzrt269Jeffrey L Cummings, Travis Morstorf and Kate Zhong2014-07-03T00:00:00ZMoving beyond the pros and cons of automating cognitive testing in pathological aging and dementia: the case for equal opportunityhttp://alzres.biomedcentral.com/articles/10.1186/s13195-014-0058-1The lack of progress over the last decade in developing treatments for Alzheimer’s disease has called into question the quality of the cognitive assessments used while also shifting the emphasis from treatment...Fri, 29 Aug 2014 00:00:00 GMThttp://alzres.biomedcentral.com/articles/10.1186/s13195-014-0058-1Keith A Wesnes2014-08-29T00:00:00Z

View all articles

The 31st International Conference of Alzheimer’s Disease International

Alzheimer’s Disease International (ADI) is pleased to announce that the 31st International Conference of Alzheimer’s Disease International, will be held at the Budapest Conference Center (Hungary) from 21 – 24 April 2015.

Register and submit your abstract now and be a part of ADI’s leading international dementia conference which covers a broad range of topics, including, research, care and policy issues. Share your latest study with a global and diverse audience and ensure your voice is heard by leaders in the field.

Key dates:
Abstract submission: Monday 23 November 2015
Early Bird Deadline: Sunday 31 January 2015

Visit the conference website here.

Featured collection: Lewy Body Dementia

Edited by Ian McKeith and James Galvin, this special series takes a translational view of Lewy body dementia from bedside to bench and back. Visit our collections page to find our full list of special series, including thematic series on Innate immunity and Traumatic brain injury.

Tweets

Advertisement

Alzheimer's Disease International logo

Alzheimer's Research & Therapy is affiliated to Alzheimer's Disease International (ADI), London, United Kingdom.

Advertisement